repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s pl

Repare Therapeutics Inc. Common Shares

Sold 39% of RPTX

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Six Montahue

Bought 35% more RPTX

Bought 714% more RPTX

Sold 30% of RPTX

Sold 83% of RPTX

Sold 70% of RPTX

Bought 100% more RPTX

New position in RPTX

Sold 50% of RPTX

Obinna Ofodum

Sold all RPTX

Alex Roznowski

Soham Bhatia

Bought 25% more RPTX

Darwin Mendoza

Bought 43% more RPTX

Arjun Banerjee

Bought 250% more RPTX